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We recently reported that retroviral pseudotypes bearing the hepatitis C virus (HCV) strain H and Con1 gly-
coproteins, genotype 1a and 1b, respectively, require CD81 as a coreceptor for virus-cell entry and infection. Sol-
uble truncated E2 cloned from a number of diverse HCV genotypes fail to interact with CD81, suggesting that
viruses of diverse origin may utilize different receptors and display altered cell tropism. We have used the
pseudotyping system to study the tropism of viruses bearing diverse HCV glycoproteins. Viruses bearing these
glycoproteins showed a 150-fold range in infectivity for hepatoma cells and failed to infect lymphoid cells. The
level of glycoprotein incorporation into particles varied considerably between strains, generally reflecting the
E2 expression level within transfected cells. However, differences in glycoprotein incorporation were not as-
sociated with virus infectivity, suggesting that infectivity is not limited by the absolute level of glycoprotein. All
HCV pseudotypes failed to infect HepG2 cells and yet infected the same cells after transduction to express
human CD81, confirming the critical role of CD81 in HCV infection. Interestingly, these HCV pseudotypes
differed in their ability to infect HepG2 cells expressing a panel of CD81 variants, suggesting subtle differences
in the interaction of CD81 residues with diverse viral glycoproteins. Our current model of HCV infection suggests
that CD81, together with additional unknown liver specific receptor(s), mediate the virus-cell entry process.
Hepatitis C virus (HCV) is an enveloped virus classified in
the Hepacivirus genus of the family Flaviviridae (32). An esti-
mated 170 million individuals are infected with HCV world-
wide. Infection is associated with the development of chronic
hepatitis, cirrhosis, and hepatocellular carcinoma. B-cell ab-
normalities, including cryoglobulinemia and an increased risk
of non-Hodgkins B-cell lymphoma, have also been reported
(11, 13, 38). The principal site of virus replication is thought to
be the liver; however, several reports suggest that HCV RNA
or proteins associate with lymphoid cells, particularly B cells
(8, 30, 49), a view consistent with the clinical abnormalities
observed in B-lymphocyte growth and function.
HCV encodes two envelope glycoproteins (gp’s) E1 and E2,
which are believed to be type I integral transmembrane pro-
teins. Our understanding of gp maturation and virus assembly
is limited by the lack of a tissue culture system supporting
particle assembly and release. In the absence of a cell culture
system, surrogate assays have been developed to study HCV-
cell attachment, including the expression of truncated ver-
sion(s) of the E2 gp (19, 43), E1E2 gp-liposomes (28), and
virus-like particles expressed in insect cell systems (6, 51).
Truncated soluble versions of E2 bind specifically to human
cells and were used to identify interactions with a number of
cell surface molecules, including CD81 (19, 43), scavenger
receptor class B type I (SR-BI) (47), and DC-specific ICAM-3
grabbing nonintegrin (DC-SIGN) (22, 35, 44). In addition,
HCV purified from human plasma is associated with low-den-
sity lipoprotein, suggesting that the virus may use the low-
density lipoprotein receptor to enter cells (2, 52).
The development of infectious retroviral pseudotypes bear-
ing unmodified HCV gp’s has provided a model system to
study HCV cell entry (4, 12, 25). Pseudotypes bearing strain H
and Con1 HCV gp’s show a restricted tropism for human liver
cell lines, infection is pH-dependent and can be neutralized by
monoclonal antibodies (MAbs) specific for E2 and by HCV-
positive human sera (3). We recently reported that the infec-
tivity of pseudotypes harboring these gp strains is CD81 de-
pendent (55). However, CD81 expression alone is not sufficient
to allow pseudotype infection of a target cell, and additional
liver specific molecule(s) are thought to be required.
HCV is grouped into six major genotypes (20 to 30% overall
sequence difference) and more than 50 subtypes (10 to 20%
difference) (39). Within an infected individual, HCV exists as
a group of different but closely related variants referred to as
a viral quasispecies, a characteristic shared by many RNA
viruses. Although variability has been documented across the
entire genome, the most variable proteins are the envelope
gp’s. Distinct gp variants have been reported between the liver
and peripheral blood mononuclear cell (PBMC) fractions, sup-
porting a model where HCV may replicate in extrahepatic sites
(29, 30, 49). This tropism is most likely determined at the level
of virus gp-receptor interaction(s). Several reports have sug-
gested that soluble E2 cloned from diverse genotypes fail to
interact with CD81, suggesting that viruses of diverse origin
may demonstrate altered cell tropism and potentially utilize
different receptors (45, 48). We have used the pseudotyping
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system to study the tropism of viruses bearing HCV gp strains
of diverse origin. HCV pseudotypes bearing these gp’s failed to
infect lymphoid cells and demonstrated a range of infectivities
for liver-derived cell lines, infection was CD81 dependent, and
some viruses differed in their ability to infect HepG2 cells
expressing variant CD81 molecules. These data suggest that
CD81 is used as a coreceptor by a wide range of HCV strains.
MATERIALS AND METHODS
Cells and antibodies. 293T (obtained from the American Type Culture Col-
lection [ATCC]), Huh-7.5 (7), Hep3B (ATCC), and HepG2 (gift of Y. Matsuura,
Osaka University) cells were propagated in Dulbecco modified Eagle medium
(DMEM) with 10% fetal bovine serum (FBS). HepG2 cells were cultured on
collagen type I-coated tissue culture plastic. Human lymphoid MT-2, Daudi, and
LAZ 221 cells (gifts of C. Cheng-Mayer, Aaron Diamond AIDS Research Cen-
ter, and E. Meffre, The Rockefeller University) were propagated in RPMI–10%
FBS.
PBMC were separated from whole blood on lymphocyte separation medium
(ICN, Costa Mesa, Calif.) by centrifugation at 800  g. PBMC were propagated
as resting cultures in RPMI–10% FBS, with or without activation with phytohe-
magglutinin (PHA; 3 g/ml) for 72 h, and subsequently maintained in RPMI–
10% FBS–interleukin-2 (20 U/ml). CD19 B lymphocytes were positively se-
lected by using immunomagnetic separation according to the manufacturer’s
protocol (MACS; Miltenyi Biotech, Auburn, Calif.). B cells fractionated in this
manner are routinely 90% pure as determined by flow cytometric analysis.
B-cell-enriched and -depleted fractions were cultured overnight at 3  106
cells/ml in RPMI–10% FBS and 1 g of pokeweed mitogen (Sigma, St. Louis,
Mo.)/ml. All cells were grown at 37°C in 5% CO2.
Murine MAbs used in the present study include 1.3.3.22 anti-CD81 (Santa
Cruz Biochemicals, Santa Cruz, Calif.), 1D6 anti-CD81 (Serotec, Ltd., Oxford,
United Kingdom), CLA1 anti-SRBI (BD Biosciences), and AC-15 anti-actin
(Sigma). Rat MAbs specific for HCV E1 and E2 were previously described (19).
Anti-E1 MAb A4 was kindly provided by H. Greenberg (Stanford University)
and anti-E1 MAb 725P was purchased from Maine Biotechnology.
PCR amplification, cloning, and sequence analysis of HCV E1E2. The plas-
mids encoding strain H and Con1 E1E2 gp’s (polyprotein residues 171 to 746),
SF162 gp160 and murine leukemia virus (MLV) envelope (env) were described
previously (25, 55). The E1E2 open reading frame (ORF) was amplified by a
nested PCR protocol from plasmid DNA encoding the infectious molecular
clones H77 (GenBank accession no. AF009606) (27), H (M67463) (26), Con1
(AJ238799) (33), HCJ4 (AF054250) (54), and HCJ6 (AF177036) (53) and from
total RNA prepared from HCV-infected plasma (HCV viral RNA levels 105/
ml) by using commercial kits (Qiagen) (23). Briefly, cDNA was synthesized in a
reaction volume of 20 l, containing 2 to 5 l of template RNA, 2.5 U of
“Multiscribe” Moloney MLV reverse transcriptase with 400 M concentrations
of each of the four deoxynucleoside triphosphates and a 200 nM concentration
of the antisense primer p7-2710 (AGC AGG AGG AGN GGC CAY ATC CCR
TAG A, where Y  C/T mixture, R  A/G, and N  A/G/C/T) in the manu-
facturer’s recommended buffer (N808-0234; ABI, Foster City, Calif.) for 2 h at
42°C. This cDNA was used as the template for PCR amplification of the E1E2
region as previously described (17). Briefly, a 50-l PCR was set up containing
2.5 l of cDNA, 2.5 U of the proofreading Expand polymerase mixture (1 681
834; Roche, Mannheim, Germany) in 1 Expand Buffer 3 (2.25 mM Mg2) with
400 M concentrations of each of the four deoxynucleoside triphosphates and
200 nM concentrations of each of the primers core813 (GAG GAC GGY RTR
AAY TAY GCA ACA GG; sense) and p7-2710. The PCR consisted of 30 cycles
of 92°C for 45 s, 45°C for 45 s, and 68°C for 300 s and was performed in an
Eppendorf thermal cycler. Then, 2 l of the completed reaction was used as a
template for a second amplification, containing the same reaction components as
described above with 200 nM concentrations of the primers core843 (CACC
ATG GGT TGC TCT TTC TCT ATC TT; sense) and E2-2580 (CTA CTA GGC
CTC AGC CTG GGC TAT CAG CAG CAT CAT CCA; antisense). This
second-round PCR comprised 25 cycles of 92°C for 35 s, 55°C for 35 s, and 68°C
for 150 s. In most cases, full-length E1E2 (OH8, CH35, CH129, OH5, CH46, and
CH54) was readily amplified by these two rounds of PCR. However, for genotype
6 (HK6), two separate but overlapping fragments covering the E1E2 region were
first amplified with primers specific for a Hong Kong 6a sequence, EUHK2 (1),
and then combined to generate full-length HK6 sequences. PCR products were
cloned into pcDNA3.1-TA (Invitrogen), and the sense and antisense strands
were sequenced (Big Dye 3.0 Terminator Kit; ABI). All sequences were depos-
ited with GenBank and have the accession numbers AY545951 to AY545980.
Pseudotype production and infection. Pseudotypes were generated by the
transfection of 293T cells (plated at 8  105 cells per well of a six-well dish 24 h
prior to transfection) with 2 g of pNL4-3.Luc.RE plasmid containing the
env-defective human immunodeficiency virus type 1 (HIV-1) proviral genome
and 2 g of expression plasmid encoding the HCV gp’s, MLV env gp, vesicular
stomatitis virus protein G (VSV-G), or an empty vector with Lipofectamine-2000
(Invitrogen, Carlsbad, Calif.) (9, 25). The supernatants were collected 48 to 72 h
posttransfection. Transfected cells were collected, washed with phosphate-buff-
ered saline (PBS), and resuspended in lysis buffer (50 mM Tris-HCl [pH 7.4], 150
mM NaCl, 1% NP-40, Complete protease inhibitors) on ice for 30 min. Lysates
were clarified by centrifugation at 4°C for 15 min at maximum speed (20,000 
g) in a microcentrifuge; and the resulting supernatants were stored at 80°C
prior to analysis.
Virus was pelleted through a sucrose cushion by layering 1 ml of cell culture
medium onto 0.3 ml of 20% (wt/vol) sucrose-PBS before centrifugation at 20,000
 g for 4 h. The medium and cushion were discarded, and the virus pellet was
resuspended in 100 l of PBS on ice. Pelleted virus was inactivated by resuspen-
sion in 1% Empigen-PBS and incubated at 56°C for 30 min. Virus and cell lysates
were tested for HIV-1 p24 antigen content by using a commercially available
HIV-1-p24 antigen enzyme-linked immunosorbent assay (ELISA) protocol
(Aalto Bio Reagents, Dublin, Ireland).
TABLE 1. Characterization of divergent HCV E1E2 sequences
Clone Genotype No. ofclones
Avg difference
(avg distance
[%])a
Genetic distance
from strain
H77 (%)
No. of potential
N-linked glycosylation
sites (E1/E2)
Sequence of epitope:
3/11 6/1a 9/75
H77 1a 1 NA 0 15 (5/11) QLINTNGSWHIN DFAQGWGP APTYSWGA
H 1a 1 NA 0.7 15 (5/10) –––––––––––– –––––––– ––––––––
OH8 1b 3 0.7 (0.04) 32.5 15 (5/10) ––V––––––––– K–D––––– V–––N––D
CH35 1b 3 3.3 (0.52) 31.1 17 (6/11) ––V––––––––– K–S––––– V––––––E
Con1 1b 1 NA 31.1 15 (5/10) ––V––––––––– A––––––– V––––––E
HCJ4 1b 1 NA 34.5 15 (5/10) ––V––––––––– W––––––– V––––––E
CH129 2a 3 1.3 (0.08) 43.9 15 (4/11) ––V––––––––– D–M––––– L–––NF–G
HCJ6 2a 1 NA 46.9 14 (4/10) ––V–S––––––– A–RV–––A ––––T––E
OH5 3a 3 1.7 (0.08) 42.6 14 (4/10) ––V––––––––– SFN––––– V–––T––G
CH46 3a 4 2.0 (0.07) 42.4 14 (4/10) ––V––––––––– SFN––––– V–––T––G
CH54 3b 3 3.7 (0.27) 43.9 14 (4/10) ––V––––––––– SFN––––– V–––T––G
C4a1 4 2 0 (0) 42.6 15 (4/11) ––––S––––––– SYG––––– V–––T––E
C5a1 5 2 1 (0.05) 43.5 15 (4/11) –––––––––––– A–D––––T N–––N––E
C6a1 6 5 7.1 (0.41) 46.6 15 (5/10) –––––––––––– ––R––––Q I–––N––E
HK6 6 3 2.7 (0.19) 45.5 16 (5/11) ––V––––––––– ––R––––Q I–––N––D
a Average number of nucleotides differing between clones. Distances were calculated by using the HKY85 method after the gaps were aligned to codon boundaries.
NA, not applicable.
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Hepatoma cell lines were seeded in 96-well plates (8  103 cells/well) 24 h
before infection. PBMC and lymphoid cells were seeded in 96-well plates (2 
105 cells/well) on the day of infection, and 100 l of virus-associated p24 nor-
malized viral supernatant, diluted in 3% FBS-DMEM plus 4 g of Polybrene/ml,
was added per well. Cells were centrifuged at 400  g for 1 h (40) and incubated
at 37°C overnight, and virus was removed, followed by incubation for a total of
72 h. Cells were lysed with 40 l of cell lysis buffer (Promega, Madison, Wis.)/
well, 35 l of lysate was tested for luciferase activity by the addition of 50 l of
luciferase substrate, and light output was measured for 10 s in a luminometer
(Lumat LB 9507). Luciferase values more than twofold the mean value obtained
for the no-env control virus were considered infectious.
In neutralization experiments MAb 3/11, specific for E2, or an irrelevant MAb
10/76b (final concentration, 5 g/ml) were incubated with pseudotype virus for
1 h at 37°C, and virus-ligand mixtures were tested for infectivity.
Quantitative ELISA. Briefly, GNA lectin (Sigma) was used to coat Immulon II
ELISA plates (Nunc) at 1 g/ml for 4 h at 37°C. After a wash with PBS, the plates
were blocked with 5% bovine serum albumin-PBS, and cell lysates or pelleted
virus were allowed to bind overnight at 4°C. A preparation of truncated E2661
was used as an internal calibrant in all ELISAs, and this allowed the comparison
of data between different assays. Bound antigen was visualized with MAbs
specific for E2 or pooled HCV-positive human sera, an anti-species immuno-
globulin G-horseradish peroxidase conjugate (Jackson Laboratories, West
Grove, Pa.) and tetramethylbenzidene (BioFX Laboratories). Absorbance values
were measured at 450 nm (Fusion Plate Reader; Perkin-Elmer, Boston, Mass.).
Transduction of cells to express CD81. Wild type and human CD81 mutants
(T163A, F186L, E188K, and D196E) were cloned into the BamHI/XhoI site of
the lentiviral vector TRIP as previously reported (55). HepG2 cells were plated
at 8  105 cells per well of a six-well dish and infected 24 h later with a packaged
lentivirus expressing the wild type and CD81 mutants (TRIP-CD81) at an ap-
proximate multiplicity of infection of 1 to 3 in DMEM–3% FBS plus 4 g of
Polybrene/ml for 12 h. Cells were stained with the CD81-specific MAb 1D6 and
phycoerythrin-conjugated secondary antibody, and positively stained cells were
sorted using a FACSVantage sorter (Becton Dickinson). CD81-positive cell
populations were seeded at 8  103 cells/well in a 96-well plate and infected 24 h
later with pseudotype viruses.
Flow cytometric fluorescence-activated cell-sorting (FACS) analysis. E2 ex-
pression was quantified as previously described (25). All cells were incubated
with an irrelevant isotype-matched immunoglobulin G or anti-E2 MAb 6/1a, and
the mean fluorescence signal(s) was determined. Expression of CD81 and SR-BI
was quantified as previously described (55). All cells were incubated with an
irrelevant isotype-matched immunoglobulin G or the antibody of interest, and
the fluorescence signal(s) was used to establish threshold values of detection for
the test MAbs. Analyses were performed by using a FACScalibur flow cytometer
(Becton Dickinson) and FlowJo software (Tree Star, San Carlos, Calif.).
RESULTS
Infectivity of pseudotype viruses bearing diverse HCV gp’s.
Recent studies have reported on the generation of infectious
retroviral pseudotypes bearing HCV gp’s from strains H (HIV-
HCV H) and Con1 (HIV-HCV Con1), genotypes 1a and 1b,
respectively. These viruses showed a restricted tropism for
human liver cells, and infection was CD81 dependent (25, 55).
To assess whether CD81 is utilized by viruses of different
genotypes, pseudotype viruses harboring diverse strains of gp’s
were generated, and their infectivity and tropism was studied.
The E1E2 ORF was PCR amplified from RNA extracted
from plasma obtained from HCV-infected individuals or chim-
panzees infected with viruses of genotypes 1 to 6 and from
plasmid DNA encoding infectious HCV molecular clones
(H77, Con1, HCJ4, and HCJ6) (Table 1). The PCR products
were cloned into the eukaryotic expression vector pcDNA3.1,
and at least three clones were sequenced to confirm genotype
and to assess intrasample sequence diversity. Genetic analysis
FIG. 1. Infectivity of pseudotypes bearing diverse HCV gp’s. Pseu-
dotype viruses were pelleted through a sucrose cushion, and the par-
ticle amounts were estimated by quantifying HIV p24 antigen. Hep3B
cells were infected with pseudotype viruses bearing a panel of diverse
HCV gp’s or no envelope gp (No env) containing 10 ng of particulate
HIV p24 antigen. At 72 h postinfection, cells were lysed and assayed
for luciferase activity. Values are the means of triplicate wells with the
standard deviations indicated and are represented as relative light
units (RLU). The values above each bar represent the relative infec-
tivity compared to the no-env control virus; values2-fold the mean of
no-env virus infection are considered infectious (shaded bars).
TABLE 2. Infectivity of pseudotypes bearing diverse HCV gp’s for hepatoma and lymphoid cells
Viral gp
Infectiona of cells (RLU [104])
Hep3B
(hepatoma cell)
Huh-7.5
(hepatoma cell)
PBMC
(donor 1)
PBMC
(donor 2)
Daudi (B
cell)
LAZ 221
(pre-B
cell)
MT-2 (T
cell)
No env 0.3 0.5 0.3 0.3 0.3 0.3 0.2
MLV 16000.0 9188.9 415.5 811.0 3,552.1 12.2 2,587.0
SF162 0.3 0.5 21.8 32.7 0.4 0.4 0.3
H77 984.9 137.8 0.4 0.4 0.5 0.3 0.4
OH8 876.4 189.4 0.3 0.4 0.3 0.4 0.3
CH35 15.5 4.8 0.2 0.3 0.3 0.3 0.2
Con1 1,329.0 312.9 0.4 0.3 0.4 0.6 0.4
HCJ4 108.8 9.7 0.3 0.3 0.5 0.4 0.4
HCJ6 38.8 16.7 0.3 0.2 0.5 0.4 0.3
CH46 0.4 0.5 0.4 0.3 0.5 0.4 0.3
C6a1 42.3 12.6 0.2 0.2 0.2 0.3 0.2
a The various cell types were infected with pseudotype viruses bearing control MLV gp (0.01 ng of HIV p24 antigen), no gp (no env), HIV SF162 gp, or a range of
HCV gp’s (10 ng of HIV p24 antigen). At 72 h postinfection, the cells were lysed and assayed for luciferase activity. Values are the means of triplicate wells. RLU,
relative light units. PBMC from two donors with or without phytohemagglutinin–interleukin-2 stimulation were tested for their ability to support pseudotype infection;
data are shown for the activated cells. Comparable data were obtained for resting PBMC, except that the HIV SF162 pseudotype failed to infect the resting cells.
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of replicate clones derived from plasma showed a low level of
intrapatient diversity (0.06 to 0.73%, Table 1); the frequencies
of synonymous and nonsynonymous changes were similar in all
samples studied (0 to 2%) and were consistent with previous
reports (10, 14–16, 34, 36, 49). Phylogenetic reconstruction
with referent sequences representative of the major subtypes
confirmed the genotype designations (Table 1; Los Alamos
HCV sequence database [http://hcv.lanl.gov]). Genetic dis-
tances between clones were considerable (up to 46%), reflect-
ing the high diversity of the E1E2 region between different
HCV genotypes.
All plasmids encoding a complete E1E2 ORF were cotrans-
fected with pNL4-3.Luc.RE into 293T cells, and pseudotype
viruses were tested for their ability to infect the hepatoma cell
line, Hep3B. Control pseudotype viruses were generated bear-
ing MLV or no envelope gp (no env) and tested for infectivity.
Previous studies have shown Hep3B to be the most permissive
cell line for pseudotypes bearing strain H and Con1 gp’s (25).
All virus preparations were normalized for particle number by
quantifying the HIV p24 antigen associated with virus after
they were pelleted through a sucrose cushion before infection.
HIV p24 can exist both as a soluble protein and as a virus-
associated antigen. We consistently observed reduced particle/
soluble p24 antigen ratios in the extracellular medium from
293T cells transfected to express HCV gp’s compared to the
no-env or MLV gp controls, suggesting that HCV gp’s affect
the secretion of HIV particles compared to soluble p24 antigen
(data not shown). Pseudotypes bearing H77, H, OH8, CH35,
Con1, HCJ4, HCJ6, and C6a1 gp’s were infectious for Hep3B
and Huh-7.5 cells compared to particles lacking an envelope gp
(no env) (Fig. 1 and Table 2). All infections that showed an
increase in luciferase signal relative to the no-env virus were
blocked by the broadly cross-reactive anti-E2 MAb 3/11 but
were unaffected by an irrelevant anti-HIV gp120 MAb, 10/76b
FIG. 2. Expression and incorporation of diverse HCV gp’s into pseudotype particles. 293T cells were cotransfected with pNL4-3.Luc.RE and
plasmids expressing representative HCV gp’s listed in Table 1 or an empty vector (No env). At 72 h posttransfection, the virus was pelleted through
a sucrose cushion. The cells and virus were lysed, and both fractions were quantified for E2 expression by ELISA and Western blotting. The total
E2 expressed per well of 293T cells (300 g of cellular protein) (A) and that incorporated into pseudotype particles (B) (25 ng of particulate HIV
p24 antigen) were measured by ELISA, and the data are expressed as optical density units (OD) at 450 nm and annotated above each bar. Virus
preparations that gave optical density signals 2-fold the mean of the no-env virus control were considered to have incorporated gp’s. Transfected
cell lysate (10 g of total protein) (C) and pelleted virus particles (D) (25 ng of particulate HIV p24 antigen) were separated by reducing
SDS-PAGE and immunoblotted for E2 (MAb 3/11) and actin (MAb AC-15). The migration of molecular mass markers is indicated in kilodaltons.
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(data not shown). Pseudotypes demonstrated a 150-fold range
in luciferase activity, which we have previously shown to be
proportional to the infectious viral titer (Fig. 1) (25).
Since many of the pseudotype viruses bearing non-genotype
1 gp’s cloned from infected plasma were not infectious for
Hep3B cells, we assessed their ability to infect PBMC, Daudi,
LAZ 221, and MT-2 cells. Pseudotypes bearing diverse HCV
gp’s were tested alongside viruses bearing control MLV enve-
lope, HIV SF162, or no gp. Viruses bearing the MLV envelope
gp infected all cell types tested with various efficiencies,
whereas pseudotypes bearing the HIV CCR-5-tropic gp160,
SF162, only infected activated PBMC (Table 2). In contrast,
none of the pseudotypes bearing HCV gp’s infected lymphoid
cells (Table 2). Since HCV RNA has been reported to prefer-
entially associate with B cells, we tested these pseudotype
viruses for their ability to infect purified resting and activated
B-cell and non-B-cell fractions from two donors. All pseudo-
type viruses failed to infect the B cells, including viruses bear-
ing MLV and VSV-G gp’s (data not shown). In conclusion,
pseudotypes bearing diverse HCV gp’s infect human hepatoma
liver cells with various efficiencies but fail to infect cells of
lymphoid origin.
Expression and incorporation of HCV gp’s. Since pseudo-
type virus infectivity is dependent upon HCV gp expression
(25), we were interested in determining whether the range of
infectivities was defined by the level of gp expression and
incorporation into particles. 293T cells cotransfected with
pNL4-3.Luc.RE and plasmids encoding the various HCV
gp’s were screened for E2 expression by quantitative ELISA
and Western blotting with anti-E2 MAb 3/11 (Fig. 2). E2 ex-
pression was confirmed for all plasmids; however, the levels
varied 3,000-fold, with strain H and H77 proteins being ex-
pressed at the highest level (Fig. 2). All clones from a single
sample showed comparable levels of E2 expression (data not
shown). The epitope recognized by MAb 3/11 was invariant
within clones from a single sample and is well conserved be-
tween divergent clones, with only four alternative sequences
observed. With the exception of HCJ6 (two changes); all se-
quences differed from H77 by a single conserved amino acid
(Table 1). However, these single amino acid changes within the
epitope could alter the binding affinity of the MAb for a par-
ticular strain, biasing our determination of E2 levels. To ad-
dress this issue, we used both a cocktail of anti-E2 MAbs (3/11,
6/1a, and 9/75; Table 1) and a mixture of human HCV sera
from individuals infected with HCV genotypes 1, 2, 3, and 5 to
realize the E2 bound in the ELISA. Comparable data were
obtained with respect to differences in expression levels be-
tween plasmids; however, the sensitivity of the ELISA was
reduced20-fold when polyclonal human sera was used as the
detecting agent (data not shown). The anti-E1 MAbs A4,
3/8ow, and 725P were able to detect E1 in lysates from cells
transfected with plasmids encoding strain H and H77 gp’s;
however, these MAbs failed to react with other gp strains (data
not shown). Analysis of cell lysates by reducing sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotting with MAb 3/11 showed an E2 species mi-
grating at 60 kDa, with some minor changes in migration
patterns observed between clones, a finding consistent with
changes in the number of predicted N-linked glycosylation sites
(Fig. 2 and Table 1). E2 expression levels observed by Western
blotting of cell lysates were consistent with the ELISA data and
varied between different HCV strains.
To quantify E2 incorporation into HIV pseudotypic parti-
cles, the virus present in the extracellular medium was pelleted
by centrifugation through a 20% sucrose cushion. Virus parti-
cles were quantified by measuring HIV p24 antigen, and 25 ng
of each preparation was evaluated by ELISA and immunoblot-
ting with anti-E2 MAb 3/11. The level of E2 incorporated into
particles varied between different gp strains, generally reflect-
ing the differences in gp expression observed in the cell lysates
(Fig. 2). An association was observed between E2 expression
levels and incorporation into particles; however, the absolute
level of incorporated gp was not a predictor of pseudotype
virus infectivity (Fig. 3). In replicate experiments, the levels of
E2 incorporated into particles varied by up to fivefold, depend-
ing on the transfection efficiency; however, the relative differ-
ences in incorporation noted between diverse gp’s were main-
tained. Quantification of the levels of E2 antigen in both the
cell and the virus preparations by ELISA demonstrated that
between 0.7 and 4.6% of the E2 antigen within the cell was
incorporated into particles. If we assume that incorporation
occurs at the plasma membrane, the observation that only a
minor fraction of the total cellular antigen is incorporated into
particles is consistent with the low level of E2 detected at the
surface of transfected 293T cells. Analysis of the incorporated
gp’s by SDS-PAGE demonstrated E2 species migrating at
ca. 60 and 100 kDa; the latter band may represent an un-
cleaved E1E2 species or a form of E2 that is resistant to SDS
treatment (Fig. 2) (18). In general, there was good agree-
ment in the inferred levels of incorporated E2 protein be-
tween the two methodologies, with the ELISA being more
sensitive.
HCV gp’s (OH5, CH54, and C5a1) failed to incorporate into
particles or to yield infectious virus (Fig. 1 and 2), whereas
viruses bearing CH46 gp’s, which appeared to incorporate E2
at levels comparable to HCJ4 and HCJ6, were not infectious.
FIG. 3. Association between cellular HCV E2 expression levels and
incorporation into pseudotype particles. Relationship between the
level of E2 expressed in cells and that incorporated into pseudotype
particles as determined by ELISA (r2  0.643, P  0.0003). HCV gp
strains OH5, CH54, and C5a1 failed to show any specific incorporation
into particles and are indicated by open circles.
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In contrast, moderate levels of infectivity were noted for pseu-
dotypes bearing low levels of CH35 and C6a1 gp’s, suggesting
that the absolute level of gp incorporated into particles is not
associated with virus infectivity. To assess the relationship be-
tween the level of incorporated gp(s) and infectivity, pseudo-
type viruses were generated by transfection of 293T cells with
pNL4-3.Luc.RE and different amounts of pH77 E1E2. Cells
were monitored for both total and cell surface-expressed E2 by
FACS and for E2 antigen levels within cell lysates and sucrose
cushion-pelleted virus by ELISA. Decreasing the H77 plasmid
concentration by 5- and 10-fold had a modest but detectable
effect on the level of cellular E2, as measured by FACS and
ELISA, suggesting that E2 expression levels were close to
saturation (Fig. 4A and B). In contrast, significant differences
were noted in the levels of E2 expressed at the cell surface and
subsequently incorporated into particles, a finding consistent
with a minor fraction of the total cellular antigen being incor-
porated into particles (Fig. 4C). However, all H77 virus prep-
arations showed comparable levels of infectivity for Hep3B
(Fig. 4D) and for Huh-7.5 cells (data not shown). These data
suggest that incorporation of functional gp’s is near saturation
and that the infectivity of particles may not be limited by the
apparent low levels at which some HCV gp’s incorporate.
Hence, the range of infectivities observed for viruses bearing
diverse HCV gp’s may not simply be to attributable differences
in gp incorporation per se but may reflect differences in their
ability to generate and transport a functional gp complex to the
cell surface and in different receptor binding and/or fusion
activities of the assembled gp complex.
HCV pseudotype infection is CD81 dependent. We previ-
ously reported that the infectivity of pseudotypes bearing strain
H and Con1 E1E2 gp’s was CD81 dependent. However, CD81
expression alone is not sufficient to confer susceptibility to
infection by HCV pseudotypes, and additional liver specific
FIG. 4. gp incorporation and infectivity of pseudotypes bearing H77 E1E2. 293T cells were cotransfected with pNL4-3.Luc.RE and different
amounts of pH77 E1E2 (2.0, 0.4, or 0.2 g) or an empty vector (No env) to produce pseudotypes with different amounts of incorporated gp’s.
(A) Transfected cells were fixed with paraformaldehyde and stained for E2 expression with (dark gray shading) or without permeabilization (light
gray shading) to detect total and cell surface E2 antigen, respectively. The data are expressed as mean fluorescence units (M.F.I.). The level of E2
in both the transfected cells (300 g of cellular protein) (B) and pelleted pseudotype particles (C) (25 ng of particulate HIV p24 antigen) was
measured by ELISA, and the data are expressed as optical density units (OD) at 450 nm. Hep3B cells were infected with pseudotype viruses bearing
different amounts of H77 gp’s or no envelope gp (No env) containing 10 (gray) and 2 ng (unshaded) of particulate HIV p24 antigen (D). At 72 h
postinfection, cells were lysed and assayed for luciferase activity. Values are the mean of triplicate wells with the indicated standard deviations and
are represented as relative light units (RLU).
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factor(s) are thought to be required (55). A recent report by
Bartosch et al. suggested that both SR-BI receptor and CD81,
in addition to liver-specific factor(s), are required for HCV
pseudotype infection (5). The HepG2 hepatoma cell line ex-
presses SR-BI but not CD81 and allows one to assess the
relative contribution(s) of these cell surface molecules for
HCV pseudotype infection (Fig. 5). HCV pseudotypes were
tested for their ability to infect parental HepG2 cells and those
transduced to express human CD81 (HepG2-CD81). A control
pseudotype virus bearing MLV envelope gp infected both
HepG2 and HepG2-CD81, whereas HCV pseudotypes only
infected HepG2 cells expressing CD81 (Fig. 5B). These data
support a role for CD81 in HCV pseudotype infection that is
conserved across diverse HCV strains.
The ability of CD81 to render HepG2 cells susceptible to
HCV pseudotype infection provides an ideal system to test the
determinants of CD81 required for infection. We previously
reported that soluble truncated E2 failed to interact with Af-
rican green monkey CD81, which differed from the human
molecule at four amino acid residues (24). Mutation of the
human CD81 sequence at each of these residues identified
amino acid 186 to be critical for its interaction with soluble E2.
However, expression of the CD81 variants T163A, F186L,
E188K, and D196E in HepG2 cells conferred comparable lev-
els of permissivity to HCV pseudotypes bearing strain H and
Con1 gp’s (55). Since pseudotype viruses bearing diverse HCV
gp’s display different infectivities for Hep3B and Huh-7.5 cells,
we compared their infectivity for HepG2 cells expressing these
variant CD81 molecules. All CD81 variants were expressed at
comparable levels on the cell surface and in 95% of cells
FIG. 5. Infectivity of pseudotype viruses bearing divergent HCV gp’s is CD81 dependent. (A) Cell surface expression of CD81 and SR-BI on
parental HepG2 cells and cells transduced to express human CD81. (B) HepG2 and HepG2-CD81cells were infected with pseudotype viruses
bearing a panel of diverse HCV gps or no envelope gp (No env) containing 10 ng of particulate HIV p24 antigen. In order to give comparable
relative light unit (RLU) signals, the MLV pseudotype virus was infected at a lower dose (0.01 ng of particulate p24 antigen). At 72 h postinfection,
cells were lysed and assayed for luciferase activity. Values are the means of triplicate wells with the indicated standard deviation. Values above each
bar represent the relative infectivity compared to the no-env control virus; values 2-fold the mean for the no-env virus infection were considered
infectious.
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(data not shown). As previously reported, a control pseudo-
virus bearing MLV envelope gp and viruses bearing strain H or
Con1 HCV gp’s infected HepG2 expressing wild-type or vari-
ant CD81 molecules equally. In contrast, viruses bearing
CH35, HCJ4, and C6a1 gp’s infected HepG2-CD81 D196E
cells with 70 to 96% reduced efficiency compared to cells ex-
pressing wild-type CD81 (Table 3). Since viruses bearing these
gp’s were generally less infectious than those bearing H, H77,
and Con1 gp’s, their reduced titers may contribute to the al-
tered permissivity of the CD81 D196E variant line. However,
when HepG2 cell lines were infected with a reduced inoculum
of virus bearing strain H gp’s, a comparable luciferase activity
was observed in all clones, suggesting that the permissivity of
the variant CD81 HepG2 cells lines was not dependent on the
infecting viral dose (Table 3). These data confirm that all of the
HCV pseudotypes require CD81 to infect HepG2 cells. How-
ever, some HCV gp’s differ in their interaction(s) with CD81
and in particular amino acid 196 appears to be an important
determinant of such differences.
DISCUSSION
In the present study we show that retroviral pseudotypes
bearing a diverse panel of HCV gp’s are infectious for liver-
derived cells and fail to infect lymphoid cells. These data are
consistent with the liver being the primary reservoir for HCV
replication in vivo and support a model where liver-specific
receptor(s) may contribute to the tissue specificity of HCV
infection. The observation that all HCV pseudotypes fail to
infect HepG2 cells and yet infect the same cells after trans-
duction to express human CD81 confirms the critical role of
CD81 in HCV infection. The inability of HepG2 cells to sup-
port HCV pseudotype infection suggests that SR-BI expression
alone is not sufficient to confer infection (5). Further clarifi-
cation of the relative contribution of CD81 and SR-BI in HCV
cell attachment and fusion awaits the identification of the liver
specific factor(s).
Pseudotypes bearing gp’s cloned from infectious molecular
clones (H77, Con1, HCJ4, and HCJ6) were all infectious for
Hep3B cells. In contrast, only three of ten virus preparations
bearing gp’s (OH8, CH35, and C6a1) cloned directly from
infected plasma were infectious. There are several possible
interpretations of these results. First, viruses in the plasma may
infect cell types not tested in the present study; however, it
should be noted that previous attempts to infect immature and
mature blood-derived dendritic cells with pseudotype viruses
bearing strain H and Con1 gp’s failed (25). Second, viruses in
the plasma may encode for a high frequency of defective gp’s,
as has been noted for HIV (31, 41, 46); however, this is un-
likely, given the high infectivity to particle number noted for a
number of related flavi- and pestiviruses (32). Third, PCR
amplification of the E1E2 ORFs from HCV-infected plasma
may have resulted in in vitro errors (37). However, in samples
from which infectious virus was obtained, all replicate clones
generated virus of comparable infectivity, suggesting that the
in vitro error rate (which we previously estimated to be 1
base/clone for this method [23]) was not an adequate explana-
tion for the lack of infectivity observed. Fourth, these gp’s may
be infectious in a native virion but defective in the retroviral
pseudotyping system, which involves gp processing and particle
assembly pathways distinct from those likely to be used by
HCV.
Several of the plasma-derived E1E2 ORFs expressed low
levels of gp compared to H77 and showed minimal incorpora-
tion into particles (Fig. 2). It is possible that immune detection
and quantitation of these diverse gp’s may misrepresent dif-
ferences in gp expression between divergent clones. However,
the epitope recognized by MAb 3/11 is of low variability, and
the changes that are observed are generally conservative (Ta-
ble 1). One method of overcoming this potential issue would be
to epitope tag the E1E2 ORFs; however, Dubuisson and co-
workers recently reported that introduction of a tag sequence
into the carboxyl regions of E1 or E2 reduced the infectivity of
pseudotypes bearing these gp’s (42). The use of a polyclonal
HCV-positive human sera mixture to detect the gp’s by ELISA
provided data comparable to that obtained with MAb 3/11,
confirming the differences in expression levels noted between
clones. An experiment to address the relationship between
HCV gp incorporation and infectivity showed that a 10-fold
reduction in the level of virion-associated E2 did not affect
viral entry, suggesting that the level of gp incorporation is not
rate limiting (Fig. 4). We have recently reported that HIV
pseudotypes incorporate a heterogeneous mixture of HCV
gp’s with respect to their glycosylation pattern, disulfide
linkages, and predicted molecular weight (18). Hence, one
possible interpretation for the differences in infectivity of
these pseudotypes is that some HCV strains express and
incorporate a greater frequency of functionally active gp’s than
others. However, at the present time it is not possible to define
the functionally active gp species and to evaluate this possibil-
ity.
Pseudotypes bearing gp’s amplified from infectious molecu-
lar clones demonstrated a 30-fold range in infectivity (Fig. 2),
which failed to associate with the level of incorporated gp(s).
Similar differences in infectivity have been reported for HIV
TABLE 3. Infectivity of pseudotypes for HepG2 cells expressing
wild-type and variant human CD81 moleculesa
Viral gp
Relative infection of HepG2 cells expressing CD81
(RLU [103])
Wild
type
CD81
T163A
CD81
F186L
CD81
E188K
CD81
D196E
No env 0.3 0.3 0.4 0.2 0.3
H77 352.0 205.7 253.8 346.8 220.1
OH8 1099.5 657.1 684.5 879.4 609.5
CH35 14.5 3.4 8.9 4.8 3.9
Con1 846.7 697.5 844.6 824.8 567.6
HCJ4 33.6 20.1 35.4 27.7 10.1
HCJ6 45.3 29.1 39.1 54.1 21.6
C6a1 22.4 28.0 31.3 21.2 3.1
H77 (reduced
inoculum)
34.5 36.7 25.9 22.4 22.8
a HepG2 cells transduced to express wild-type and variant CD81 molecules
were infected with pseudotype viruses bearing no gp (No env) or a range of HCV
gp’s containing 10 ng of particulate HIV p24 antigen. Control MLV pseudotype
infections were performed with a reduced inoculum of 0.01 ng of HIV p24
antigen. HIV-HCV H77 was also infected with a reduced inoculum of 1 ng of
particulate HIV p24 antigen. At 72 h postinfection, the cells were lysed and
assayed for luciferase activity. Luciferase values for HCV pseudotype infection of
each cell line were normalized relative to the signal obtained from an MLV
infection of the same target cell.
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particles bearing envelope gp’s cloned from diverse genotypes
and has been attributed to variations in affinity for CD4 and
chemokine coreceptors (20, 21, 23, 50). The soluble form of
HCV strain H E2 has been used extensively as a model to study
HCV-CD81 interactions, and several reports have shown that
soluble E2 gp’s cloned from other genotypes fail to interact
with CD81 (45, 48). The minimal interaction of non-strain H
E2 gp’s with CD81 may simply reflect differences in gp folding
and conformation of the truncated protein or may represent
true differences in the affinity of E2 gp’s for CD81. Pseudotype
viruses bearing the Con1 gp’s infect cells in a CD81-dependent
manner, and yet a truncated form of Con1 E2 shows negligible
interaction with CD81, suggesting that pseudotype virus inter-
action with CD81 is more complex than the interaction of
soluble E2 with CD81 and is likely to involve other cellular
molecules (55). It is interesting that viruses bearing HCJ4,
CH35, and C6a1 gp’s infected HepG2 cells expressing the
D196E CD81 variant less efficiently than cells expressing wild-
type CD81 (Table 3). These data suggest that there may be
subtle differences in the CD81 residues interacting with diverse
viral gp’s; however, all viruses studied to date require CD81 to
initiate infection of a target cell. Our current model of HCV
infection suggests that CD81, together with additional un-
known liver-specific receptor(s), mediates the virus-cell entry
process, and it is likely that interaction of gp’s with these
factors will be a critical determinant in defining the permissiv-
ity of a cell to HCV infection.
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